The Cost Savings Potential of Biosimilar Drugs in the ...

Description of Existing Estimates of Cost Savings Overall, studies estimating the short to mid-term (i.e., within ten years) savings from biosimilars arrive at a range of 10 to 50 percent reduction in unit price. In other words, if all else is held constant, and if every patient is transitioned to a biosimilar, spending on ................
................